PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Boosters On HIV Patients

01/12/2022 | 05:57am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.54% 154.13 Delayed Quote.-40.07%
DOW JONES AFRICA TITANS 50 INDEX -0.36% 504.48 Real-time Quote.-5.57%
DOW JONES SOUTH AFRICA(ZAR) -1.43% 1885.39 Real-time Quote.-3.64%
JOHNSON & JOHNSON -0.79% 179.93 Delayed Quote.6.04%
ON SEMICONDUCTOR CORPORATION 4.00% 56.68 Delayed Quote.-19.76%
PFIZER, INC. 0.78% 53.845 Delayed Quote.-9.55%
S&P AFRICA 40 INDEX -0.73% 161.81 Real-time Quote.-6.89%
All news about PFIZER, INC.
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-..
AQ
10:19aWALL STREET STOCK EXCHANGE : Investors are eagerly awaiting the Fed minutes
10:02aPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08:36aPFIZER INC : Goldman Sachs reiterates its Neutral rating
MD
07:33aPfizer Launches Initiative to Sell Medicines, Vaccines to 45 Low-Income Countries on a ..
MT
06:29aMARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
06:00aDavos updates | Zelenskyy says Ukraine won't give up land
AQ
03:37aPfizer to Make Patented Treatments Available at Cost in Lower-Income Countries
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,91x
Yield 2022 3,04%
Capitalization 300 B 300 B -
EV / Sales 2022 2,74x
EV / Sales 2023 3,65x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,41 $
Average target price 57,66 $
Spread / Average Target 7,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-9.55%299 678
JOHNSON & JOHNSON6.04%477 336
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494
NOVO NORDISK A/S1.61%244 637